Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
Free Cash Flow
Income Statement
Cash Flow Statement
Balance Sheet
Operating metrics disclosed this quarter
Read from the filing itself — XBRL does not carry these, so no standard financial dataset has them.
ALYFTREK Reimbursed Countries
25
In the second quarter of 2026, we secured reimbursement for ALYFTREK in four additional countries, including Spain, bringing the total number of countries where ALYFTREK is reimbursed to 25. We also signed a letter of intent with the Pan-Canadian Pharmaceutical Alliance for reimbursement of ALYFTREK for eligible patients six years of age and older in Canada.
JOURNAVX Individuals With Reimbursed Access
260.0M
We have reached agreements with two additional major pharmacy benefit managers for Medicare Part D coverage of JOURNAVX. As a result, seniors covered by three of the four major Medicare Part D pharmacy benefit managers have reimbursed access. Twenty-three states provide coverage for JOURNAVX via Medicaid. In total, approximately 260 million individuals have reimbursed access to JOURNAVX across a wide range of commercial and government payers.
JOURNAVX Medicaid States With Coverage
23
We have reached agreements with two additional major pharmacy benefit managers for Medicare Part D coverage of JOURNAVX. As a result, seniors covered by three of the four major Medicare Part D pharmacy benefit managers have reimbursed access. Twenty-three states provide coverage for JOURNAVX via Medicaid. In total, approximately 260 million individuals have reimbursed access to JOURNAVX across a wide range of commercial and government payers.
JOURNAVX Medicare Part D PBMs With Reimbursed Access
3
We have reached agreements with two additional major pharmacy benefit managers for Medicare Part D coverage of JOURNAVX. As a result, seniors covered by three of the four major Medicare Part D pharmacy benefit managers have reimbursed access. Twenty-three states provide coverage for JOURNAVX via Medicaid. In total, approximately 260 million individuals have reimbursed access to JOURNAVX across a wide range of commercial and government payers.
Earnings Release
EX-99.1 2 ex-991_q22026.htm EX-99.1 Document Vertex Reports Second Quarter 2026 Financial Results — Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025 — — Raising full-year revenue guidance to $13.1 billion to $13.2 billion — — Continued progress across research and devel
EX-99.1 2 ex-991_q22026.htm EX-99.1 Document Vertex Reports Second Quarter 2026 Financial Results — Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025 — — Raising full-year revenue guidance to $13.1 billion to $13.2 billion — — Continued progress across research and development pipeline; povetacicept PDUFA date November 30th — — Entered into agreement to acquire Crinetics Pharmaceuticals, with closing anticipated in the third quarter of 2026 — BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 revenue guidance. “Vertex delivered excellent second quarter results, expanding our leadership in cystic fibrosis; delivering strong revenue growth in sickle cell disease, beta thalassemia, and acute pain; and with the pending acquisition of...
Source
Exhibit EX-99.1
0000875320-26-000256
Filed August 3, 2026 at 8:09 PM UTC. The figures above are from the audited statements, not from this release.